Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer

Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer

Michalis Liontos, Maria Lykka, Meletios-Athanasios Dimopoulos, Aristotle Bamias Oncology Department, Therapeutics Clinic, Medical School, University of Athens, Athens, Greece Abstract: Angiogenesis has been implicated in ovarian cancer pathogenesis. Bevacizumab, an anti-vascular endothelial growth...

Full description

Bibliographic Details
Main Authors: Liontos M, Lykka M, Dimopoulos MA, Bamias A
Format: Article
Language:English
Published: Dove Medical Press 2014-10-01
Series:OncoTargets and Therapy
Online Access:http://www.dovepress.com/profile-of-trebananib-amg386-and-its-potential-in-the-treatment-of-ova-peer-reviewed-article-OTT

Internet

http://www.dovepress.com/profile-of-trebananib-amg386-and-its-potential-in-the-treatment-of-ova-peer-reviewed-article-OTT

Similar Items